Zurueck zur Suche

Reporte zur Charge T013205

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

29Reporte angezeigt
1Todesfaelle
1Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
MI 9 CA 4 TX 3 OH 3 NV 1 PA 1 AZ 1 NY 1 AR 1 TN 1 IL 1 CO 1

VAERS 1499111

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

kritisch
Staat
CA
Alter
-
Geschlecht
M
Eingang
25.06.2022
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
1
Route/Site
IM / LL
Tod: ja Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Adenovirus test Anaemia Biopsy lung abnormal Bronchoalveolar lavage abnormal Cardiogenic shock Chemotherapy Coagulopathy Cytomegalovirus test negative Death Disease complication Gene sequencing Haemophagocytic lymphohistiocytosis Immunoglobulin therapy Measles Hepatosplenomegaly Herpes simplex test negative Histology Immunosuppressant drug therapy

Symptomtext

vaccine-strain measles; hemophagocytic lymphohistiocytosis; vaccine-strain measles/vaccine-strain varicella; Litarature report: This literature marketed report has been received from the authors of a published article, titled as stated above, and refers to a 19-month-old male was diagnosed with intermediate risk, PRETEXT Ill P+ hepatoblastoma at 14 months of age and treated per AHEP1531 (vincristine/cisplatin/doxorubicin/5-fluorouracil). On an unknown date, the patient was vaccinated with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II) subcutaneous injection, unk, administered for prophylaxis (strength, dose, lot #, expiry date, and route of administration were not provided). On an unknown date, 11 days after receiving measles-mumps-rubella and varicella vaccines the patient treated per AHEP1531 with vincristine, cisplatin, oxorubicin and 5-fluorouracil for intermediate risk, PRETEXT Ill P+ hepatoblastoma. After two cycles of treatment, he developed skin lesions along his scalp, thigh, and groin with vaccine-strain varicella viremia, treated with acyclovir. The subsequent three months of chemotherapy were complicated by fevers and progressive lung infiltrates with no identified etiology. Despite broad anti-infective coverage and chemotherapy being withheld, progression of his nodules led to an extensive evaluation for bacterial, fungal and viral causes. A lung biopsy showed nodular histiocytic infiltrates with reactive multinucleate cells. Polymerase chain reaction testing and histopathology of the sample were negative for tuberculosis, varicella, adenovirus, herpes simplex and cytomegalovirus. Eventually, next-generation sequencing of a bronchoalveolar lavage sample revealed measles, later confirmed as vaccine-strain through the Center for Disease Control. He developed persistent fevers with worsening anemia, thrombocytopenia, coagulopathy, hepatosplenomegaly, and cardiogenic shock. Ferritin was elevated at 39 994 ng/mL and soluble IL-2R was 3544 U/ml. He was diagnosed with hemophagocytic lymphohistiocytosis (HLH) per HLH-2004 criteria. Rapid whole-genome sequencing was negative for primary HLH and other inborn errors of immunity. He began immunosuppressive therapy (dexamethasone and etoposide) for secondary HLH and Emapalumab-lzsg due to poor upfront response. Measles-directed therapy (ribavirin, IVIG and vitamin A) was initiated once measles was confirmed. Despite these interventions, he succumbed to complications from measles and secondary HLH two weeks after starting HLH-directed therapy. The reporter considered hemophagocytic lymphohistiocytosis to be related to measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II). The reporter considered vaccine-strain measles to be related to measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II). The reporter considered vaccine-strain measles/vaccine-strain varicella to be related to measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live (M-M-R II). Upon internal review, the events vaccine-strain measles and hemophagocytic lymphohistiocytosis were determined to be medically significant. A copy of the published article is attached as further documentation of the patient's experience. This is one of three cases derived from the same literature article.; Sender's Comments: US-009507513-2206USA006539: US-009507513-2206USA006540:; Reported Cause(s) of Death: vaccine-strain measles; hemophagocytic lymphohistiocytosis

Weitere VAERSDATA-Felder
Praegender Schweregrund
Death
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
Hepatoblastoma (14 months of age)
Vorgeschichte
-
Andere Medikamente
VARIVAX; VINCRISTINE; CISPLATIN; DOXORUBICIN; FLUOROURACIL 5
Allergien
-
Vorherige Impfungen
-

VAERS 1126452

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

schwer
Staat
-
Alter
7,0
Geschlecht
M
Eingang
21.04.2021
Impfdatum
11.03.2021
Beginn
13.03.2021
Tage bis Beginn
2,0
Dosis
2
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: unbekannt Erholt: ja
Apnoeic attack Bartonella test negative Blood ethanol normal Blood immunoglobulin G normal Blood immunoglobulin M normal Blood lactic acid normal CSF culture negative CSF glucose normal CSF protein normal CSF red blood cell count positive CSF test abnormal Headache Lumbar puncture abnormal Pyrexia Seizure CSF white blood cell count increased Computerised tomogram head normal Cryptococcus test

Symptomtext

patient had a seizure, fever and headache. started with a headache the day after receiving vaccines, then had seizure on day 2 which brought the child to the hospital. went on to develop status epilepticus refractory to first line medications.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Intensive care
Hospital-Tage
-
Labordaten
LP with CSF (negative viral panel) on 3/13
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none
Allergien
none
Vorherige Impfungen
-

VAERS 1131175

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

mild
Staat
MI
Alter
1,0
Geschlecht
U
Eingang
25.03.2021
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Rash

Symptomtext

rash covering their whole body; received their first dose of VAQTA, along with MMR II and VARlVAX; This spontaneous report as received from a physician refers to a 12 month old patient. The patient's medical history, concurrent conditions and concomitant therapies were not provided. On an unknown date, the patient was vaccinated with hepatitis a vaccine, inactivated(VAQTA) lot # T013205 expiration date 03-DEC-2021; 0.5 milliliter per intramuscular route along with measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) and varicella virus vaccine live (oka/merck)(VARIVAX), all for prophylaxis (strength, dose, route, lot# and expiration date were not provided). On an unknown date, the patient experienced a rash covering their whole body. The outcome of the event was not provided. The causal relationship between the event and the suspect therapies was not provided. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability

Weitere VAERSDATA-Felder
Praegender Schweregrund
Rash
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 1403065

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

mild
Staat
TX
Alter
11,0
Geschlecht
M
Eingang
18.03.2021
Impfdatum
18.01.2021
Beginn
18.01.2021
Tage bis Beginn
0,0
Dosis
2
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Injection site erythema Injection site vesicles Pruritus Skin tightness Vaccination site swelling

Symptomtext

The night of the day of the vaccines were placed, the patient noted redness and mild swelling at both upper arms at vaccine sites. Despite po Benadryl and ice applications, pt developed some itching, but significant progression of redness and swelling at vaccine site of right arm, but circumferentially taught and swellings at left arm with fine vesicles at Hep A site.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
none known
Allergien
NKDA or other allergies
Vorherige Impfungen
-

VAERS 1109197

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

mild
Staat
NV
Alter
1,1
Geschlecht
F
Eingang
17.03.2021
Impfdatum
12.03.2021
Beginn
14.03.2021
Tage bis Beginn
2,0
Dosis
1
Route/Site
IM / LG
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Hypophagia Irritability Nasal congestion Pyrexia Rash Urine output decreased

Symptomtext

Fever 2 days post vaccination through day 4 Rash on extremities day 4 and spread to face and trunk day 5 Congestion since day 2 Irritability Decreased oral intake and urine output

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pyrexia
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
premature birth GERD
Andere Medikamente
famotidine
Allergien
-
Vorherige Impfungen
-

VAERS 1074146

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

mild
Staat
MI
Alter
-
Geschlecht
U
Eingang
05.03.2021
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
2
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Rash

Symptomtext

rash covering their whole body; This spontaneous report as received from a physician refers to a 20-month-old patient. There was no information about the patient's medical history, concurrent conditions or concomitant medication. On an unknown date, the patient was vaccinated with a second hepatitis a vaccine, inactivated (VAQTA)prefilled syringe,dose:0.5 milliliter, lot # T013205, expiration date not reported, but upon internal validation established as 03-DEC-2021,intramuscularly for prophylaxis reported as hep A vaccination. On an unknown date, the patient experienced rash covering their whole body. The patient received unspecified treatment. The outcome of rash was unknown. The causal relationship between the aforementioned event hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9) or quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) was not reported. This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability; Sender's Comments: US-009507513-2102USA008560:

Weitere VAERSDATA-Felder
Praegender Schweregrund
Rash
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 1053814

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

mild
Staat
PA
Alter
4,0
Geschlecht
M
Eingang
25.02.2021
Impfdatum
15.02.2021
Beginn
17.02.2021
Tage bis Beginn
2,0
Dosis
2
Route/Site
- / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site pruritus Injection site swelling Pain in extremity

Symptomtext

Had "4yr shots" on 2/15/21 and then 2 days later, got 'bump/swelling" on his L upper arm. Mom was using warm compresses and mom gave Motrin x1 yesterday for arm pain. Child also c/o itching to area. mom advised to apply warm compress for at least 10mins (not a lukewarm wash cloth) or let him take a warm shower and focus on L arm, or bath OK to give OTC Motrin prn pain Monitor for worse swelling, pain or fever, drainage- then needs to call, RTO or ER

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site pruritus
Hospital-Tage
-
Labordaten
none
Aktuelle Erkrankungen
no known allergies
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1044895

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

mild
Staat
TX
Alter
1,0
Geschlecht
M
Eingang
21.02.2021
Impfdatum
19.02.2021
Beginn
20.02.2021
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Gait disturbance Injection site pain

Symptomtext

Leg pain with difficulty walking and redness starting within 12 hours of vaccine which led to an additional office visit

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site pain
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 967687

UNKNOWN MANUFACTURER · VACCINE NOT SPECIFIED (OTHER) · Charge T013205

mild
Staat
-
Alter
1,0
Geschlecht
F
Eingang
23.01.2021
Impfdatum
12.01.2021
Beginn
20.01.2021
Tage bis Beginn
8,0
Dosis
1
Route/Site
IM / LG
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Pyrexia Rash erythematous Rash papular

Symptomtext

Fever for 2 days and a red raised rash now

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pyrexia
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1962785

MERCK & CO. INC. · HEP A (VAQTA) · Charge t013205

gering
Staat
OH
Alter
-
Geschlecht
U
Eingang
20.12.2021
Impfdatum
09.12.2021
Beginn
09.12.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Expired product administered No adverse event

Symptomtext

Confirmed with caller no other AE occurred; an expired dose of VAQTA was administered today; This spontaneous report was received from a registered nurse and refers to a patient of unknown age and gender. No information regarding the patient's concurrent conditions, medical history, drug reactions or allergies and concomitant medications was provided. On 09-DEC-2021, the patient was vaccinated with expired dose of hepatitis a vaccine, inactivated(VAQTA) 1 dose, lot # t013205, expiration date: 03-DEC-2021 (dose number, exact dose and route of administration were not reported) for prophylaxis (expired product administered). No other adverse event (AE) occurred (no adverse event). The administered dose did not have any temperature excursions prior to administration.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Expired product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 1533890

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
TX
Alter
-
Geschlecht
U
Eingang
07.08.2021
Impfdatum
13.07.2021
Beginn
13.07.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
OT / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product temperature excursion issue

Symptomtext

No additional AE/PQC reported.; Caller reported vaccine administered after temperature excursion.; This spontaneous report has been received from a nurse and a consumer referring to an unspecified age and gender patient. No information was provided regarding the patient's pertinent medical history, concomitant medications, past drug reactions, or allergies. On 13-JUL-2021, the patient was vaccinated with a 0.5 milliliters (mL) intramuscular dose of Hepatitis A Vaccine, Inactivated (VAQTA) for prophylaxis (lot number T013205, was verified to be valid for syringe formulation; the expiration date was reported as 12-MAR-2021, but upon internal verification was established as 03-DEC-2021) (dose number, vaccination scheme frequency, and anatomical site of administration were not provided). The involved vaccine was exposed to a temperature excursion of 9.6 degrees Celsius during a time frame of 11 minutes, which was detected by a data logger (product storage error). No previous temperature excursions were reported. No additional adverse events were reported. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet criteria for reportability

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product temperature excursion issue
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE
Allergien
-
Vorherige Impfungen
-

VAERS 1413692

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
MI
Alter
-
Geschlecht
U
Eingang
21.06.2021
Impfdatum
07.06.2021
Beginn
07.06.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

No additional adverse effect reported; vaccine that underwent a temperature excursion was administered; Information has been received from a medical assistant concerning a patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, concomitant medications, or drug reactions/allergies. It was reported that hepatitis a vaccine, inactivated (VAQTA) (lot # T013205, expiration date was reported as 02-DEC-2021 but upon internal validation established as 03-DEC-2021; lot # T023913, expiration date was reported as 30-MAR-2022 but upon internal validation established as 31-MAR-2022; lot # T018229, expiration date was reported as 13-DEC-2021 but upon internal validation established as 14-DEC-2021) underwent a temperature excursion. On 07-JUN-2021, the patient was vaccinated with an improperly stored dose of hepatitis a vaccine, inactivated (VAQTA) (dose and route were not reported) for prophylaxis. Information for which lots were given to patient not provided. The vaccine was exposed the temperature excursion above 46 Fahrenheit degrees (47.2 Fahrenheit degrees) for 52 minutes (product storage error). The data logger was involved. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet criteria for reportability; Sender's Comments: US-009507513-2106USA004356:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE
Allergien
-
Vorherige Impfungen
-

VAERS 1413691

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
MI
Alter
-
Geschlecht
U
Eingang
21.06.2021
Impfdatum
07.06.2021
Beginn
07.06.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

No additional adverse effect reported; vaccine that underwent a temperature excursion was administered; Information has been received from a medical assistant concerning a patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, concomitant medications, or drug reactions/allergies. It was reported that hepatitis a vaccine, inactivated (VAQTA) (lot # T013205, expiration date was reported as 02-DEC-2021 but upon internal validation established as 03-DEC-2021; lot # T023913, expiration date was reported as 30-MAR-2022 but upon internal validation established as 31-MAR-2022; lot # T018229, expiration date was reported as 13-DEC-2021 but upon internal validation established as 14-DEC-2021) underwent a temperature excursion. On 07-JUN-2021, the patient was vaccinated with an improperly stored dose of hepatitis a vaccine, inactivated (VAQTA) (dose and route were not reported) for prophylaxis. Information for which lots were given to patient not provided. The vaccine was exposed the temperature excursion above 46 Fahrenheit degrees (47.2 Fahrenheit degrees) for 52 minutes (product storage error). The data logger was involved. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet criteria for reportability; Sender's Comments: US-009507513-2106USA004356:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 1413690

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
MI
Alter
-
Geschlecht
U
Eingang
21.06.2021
Impfdatum
08.06.2021
Beginn
08.06.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

No additional adverse effect reported; vaccine that underwent a temperature excursion was administered; Information has been received from a medical assistant concerning a patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, concomitant medications, or drug reactions/allergies. It was reported that hepatitis a vaccine, inactivated (VAQTA) (lot # T013205, expiration date was reported as 02-DEC-2021 but upon internal validation established as 03-DEC-2021; lot # T023913, expiration date was reported as 30-MAR-2022 but upon internal validation established as 31-MAR-2022; lot # T018229, expiration date was reported as 13-DEC-2021 but upon internal validation established as 14-DEC-2021) underwent a temperature excursion. On 08-JUN-2021, the patient was vaccinated with an improperly stored dose of hepatitis a vaccine, inactivated (VAQTA) (dose and route were not reported) for prophylaxis. Information for which lots were given to patient not provided. The vaccine was exposed the temperature excursion above 46 Fahrenheit degrees (47.2 Fahrenheit degrees) for 52 minutes (product storage error). The data logger was involved. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet criteria for reportability; Sender's Comments: US-009507513-2106USA004356:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE); VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 1413689

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
MI
Alter
-
Geschlecht
U
Eingang
21.06.2021
Impfdatum
09.06.2021
Beginn
09.06.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

No additional adverse effect reported; vaccine that underwent a temperature excursion was administered; Information has been received from a medical assistant concerning a patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, concomitant medications, or drug reactions/allergies. It was reported that hepatitis a vaccine, inactivated (VAQTA) (lot # T013205, expiration date was reported as 02-DEC-2021 but upon internal validation established as 03-DEC-2021; lot # T023913, expiration date was reported as 30-MAR-2022 but upon internal validation established as 31-MAR-2022; lot # T018229, expiration date was reported as 13-DEC-2021 but upon internal validation established as 14-DEC-2021) underwent a temperature excursion. On 09-JUN-2021, the patient was vaccinated with an improperly stored dose of hepatitis a vaccine, inactivated (VAQTA) (dose and route were not reported) for prophylaxis. Information for which lots were given to patient not provided. The vaccine was exposed the temperature excursion above 46 Fahrenheit degrees (47.2 Fahrenheit degrees) for 52 minutes (product storage error). The data logger was involved. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet criteria for reportability; Sender's Comments: US-009507513-2106USA004356:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE); VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 1413688

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
MI
Alter
-
Geschlecht
U
Eingang
21.06.2021
Impfdatum
09.06.2021
Beginn
09.06.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

No additional adverse effect reported; vaccine that underwent a temperature excursion was administered; Information has been received from a medical assistant concerning a patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, concomitant medications, or drug reactions/allergies. It was reported that hepatitis a vaccine, inactivated (VAQTA) (lot # T013205, expiration date was reported as 02-DEC-2021 but upon internal validation established as 03-DEC-2021; lot # T023913, expiration date was reported as 30-MAR-2022 but upon internal validation established as 31-MAR-2022; lot # T018229, expiration date was reported as 13-DEC-2021 but upon internal validation established as 14-DEC-2021) underwent a temperature excursion. On 09-JUN-2021, the patient was vaccinated with an improperly stored dose of hepatitis a vaccine, inactivated (VAQTA) (dose and route were not reported) for prophylaxis. Information for which lots were given to patient not provided. The vaccine was exposed the temperature excursion above 46 Fahrenheit degrees (47.2 Fahrenheit degrees) for 52 minutes (product storage error). The data logger was involved. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet criteria for reportability; Sender's Comments: US-009507513-2106USA004356:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE
Allergien
-
Vorherige Impfungen
-

VAERS 1413687

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
MI
Alter
-
Geschlecht
U
Eingang
21.06.2021
Impfdatum
11.06.2021
Beginn
11.06.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

No additional adverse effect reported; vaccine that underwent a temperature excursion was administered; Information has been received from a medical assistant concerning a patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, concomitant medications, or drug reactions/allergies. It was reported that hepatitis a vaccine, inactivated (VAQTA) (lot # T013205, expiration date was reported as 02-DEC-2021 but upon internal validation established as 03-DEC-2021; lot # T023913, expiration date was reported as 30-MAR-2022 but upon internal validation established as 31-MAR-2022; lot # T018229, expiration date was reported as 13-DEC-2021 but upon internal validation established as 14-DEC-2021) underwent a temperature excursion. On 11-JUN-2021, the patient was vaccinated with an improperly stored dose of hepatitis a vaccine, inactivated (VAQTA) (dose and route were not reported) for prophylaxis. Information for which lots were given to patient not provided. The vaccine was exposed the temperature excursion above 46 Fahrenheit degrees (47.2 Fahrenheit degrees) for 52 minutes (product storage error). The data logger was involved. There was no previous temperature excursion. No adverse effects were reported. This is one of several reports received from the same reporter. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet criteria for reportability; Sender's Comments: US-009507513-2106USA004356:

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE); VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 1403549

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
MI
Alter
19,0
Geschlecht
M
Eingang
16.06.2021
Impfdatum
16.06.2021
Beginn
16.06.2021
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Interchange of vaccine products Underdose

Symptomtext

Patient was administered a Pediatric dose of Hepatitis A. Caught before client left office. Administered the correct dose of Hep A (Adult). Patient informed of mistake and agreed to take the correct dose.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Interchange of vaccine products
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
none
Vorgeschichte
none
Andere Medikamente
na
Allergien
none
Vorherige Impfungen
-

VAERS 1385343

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
AZ
Alter
1,5
Geschlecht
F
Eingang
09.06.2021
Impfdatum
02.06.2021
Beginn
02.06.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / LL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Extra dose administered

Symptomtext

Medical Asistant administered Varicella and Proquad resulting in patient recieveing 2 varicella doses.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
Premarin Cream 0.625mg
Allergien
NKDA
Vorherige Impfungen
-

VAERS 1115013

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
NY
Alter
-
Geschlecht
U
Eingang
19.03.2021
Impfdatum
-
Beginn
-
Tage bis Beginn
-
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Inappropriate schedule of product administration

Symptomtext

The vaccine was given 6 weeks and 6 days earlier than the recommended 6-18 month range; no adverse event; This spontaneous report was received from a nurse, concerning a currently 15-year-old patient of unknown age. No information was provided regarding the patient's pertinent medical history, concomitant medications and previous drug reactions or allergies. On an unknown date, the patient was vaccinated with the first dose of hepatitis a vaccine, inactivated (VAQTA) (dose, frequency, route of administration, anatomical location, vaccination scheme, lot number and expiration date were not reported) as prophylaxis. On an unspecified date, the patient received the second dose of hepatitis a vaccine, inactivated (VAQTA) (lot number T013205, which was verified to be a valid lot number, expiration date reported and upon internal validation established as 03-DEC-2021) (dose, frequency, route of administration, anatomical location and vaccination scheme were not reported) as prophylaxis. According to the nurse, the second dose of the hepatitis a vaccine, inactivated (VAQTA) was given earlier than the recommendations in the prescribing information. The vaccine was given 6 weeks and 6 days earlier than the recommended 6-18 month range (inappropriate schedule of product administration). No additional adverse events were reported. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability

Weitere VAERSDATA-Felder
Praegender Schweregrund
Inappropriate schedule of product administration
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 1071463

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
AR
Alter
3,0
Geschlecht
F
Eingang
04.03.2021
Impfdatum
02.03.2021
Beginn
02.03.2021
Tage bis Beginn
0,0
Dosis
3
Route/Site
IM / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Vaccination error

Symptomtext

NONE. VACCINES WERE SUPPOSED TO BE GIVEN TO SIBLING. NO ADVERSE REACTION NOTED.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Vaccination error
Hospital-Tage
-
Labordaten
NONE
Aktuelle Erkrankungen
NONE
Vorgeschichte
NONE
Andere Medikamente
NONE
Allergien
NKA
Vorherige Impfungen
-

VAERS 1068340

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
TN
Alter
1,2
Geschlecht
U
Eingang
03.03.2021
Impfdatum
29.01.2021
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

incorrect product storage; No additional adverse events reported; This spontaneous report was received from an administrator via a Nurse, referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions and concomitant medications were not provided. On 29-JAN-2021, the patient was vaccinated with improperly stored dose of hepatitis a vaccine, inactivated (VAQTA) which had a lot # T013204 with expiration date on 03-DEC-2021 (dose, frequency and route of administration were not reported) for prophylaxis. Other dose of hepatitis a vaccine, inactivated (VAQTA) with lot # T013204 and expiration date on 03-DEC-2021 was also improperly stored. However no adverse events were mentioned. It was reported that the vaccines were exposed to temperature of -7.9 Centigrade range for a time frame of 52 minutes and -10.5 for 52 minutes The temperature excursion was recorded by a data logger and no previous excursions were reported for the vaccines. There was no product quality complaint involved. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE); VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 1035567

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
OH
Alter
1,1
Geschlecht
U
Eingang
17.02.2021
Impfdatum
01.02.2021
Beginn
01.02.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

No additional AE; Improperly stored dose was administered; This spontaneous report was received from a nurse and refers to a 13-month-old patient of unknown gender. Their concurrent conditions, medical history and concomitant therapies were not provided. On 01-FEB-2021, the patient was vaccinated with an improperly stored hepatitis A vaccine, inactivated (VAQTA) 0.5 mL, lot number: T013205, expiration date: 03-DEC-2021 (strength, frequency and route of administration were not reported) as prophylaxis. Administered dose of vaccine experienced a temperature excursion of 48 (unit not reported) for 24 hours and 45 minutes. Digital data logger was involved. There was no previous temperature excursion noted. There was no additional adverse event reported. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp. ; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 1030180

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
OH
Alter
-
Geschlecht
U
Eingang
15.02.2021
Impfdatum
01.02.2021
Beginn
01.02.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
No adverse event Product storage error

Symptomtext

no adverse event; improperly stored dose was administered; This spontaneous report was received from a nurse and refers to a 12-month-old patient. The patient's concurrent conditions, medical history and concomitant therapies were not reported. On 01-FEB-2021, the patient was vaccinated with a improperly stored dose of hepatitis a vaccine, inactivated (VAQTA) 0.5 ml, lot# T013205, expiry date 03-DEC-2021 (route of administration was not reported) for prophylaxis. The vaccine underwent temperature excursion of 48 (not further specified) for 24 hours and 45 minutes. There were no previous temperature excursions. The call was because of digital data logger. No adverse event was reported. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability

Weitere VAERSDATA-Felder
Praegender Schweregrund
No adverse event
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 1010953

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
IL
Alter
-
Geschlecht
U
Eingang
08.02.2021
Impfdatum
25.01.2021
Beginn
25.01.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

Caller is reporting that an improperly stored vaccine was administered on 25JAN202 l.; Information has been received from a nurse, referring to a patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 25-JAN-2021, the patient was vaccinated with an improperly stored dose of hepatitis a vaccine, inactivated(VAQTA) lot # T013205, expiration date reported on 02-DEC-2021, but upon internal validation established as 03-DEC-2021 (anatomical location and administration route were not reported) and with an improperly stored dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live(M-M-R II) lot # S004119 expiration date reported on 10-FEB-2021, but upon internal validation established as 11-FEB-2021 (anatomical location and administration route were not reported) both vaccines as prophylaxis. The vaccines had a temperature excursion of above 9 Celsius (?C) (13.4 ?C), during 2 hours and 9 minutes. It was confirm that a digital data logger was involved. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck. devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not suggest a causal association with the device or device constituent

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-

VAERS 988619

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
CA
Alter
1,0
Geschlecht
F
Eingang
29.01.2021
Impfdatum
29.01.2021
Beginn
29.01.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Erythema

Symptomtext

VERIFIED WITH STAFF. KEPT 10-15 MIN REACTION NOTICED. INFORMED DR. AND ORDERED BENADRYL

Weitere VAERSDATA-Felder
Praegender Schweregrund
Erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
NO KNOWN ALLERGIES
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
LOCALIZED RED~Measles + Mumps + Rubella + Varicella (no brand name)~1~1.00~Patient

VAERS 985021

MERCK & CO. INC. · MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) · Charge T013205

gering
Staat
CA
Alter
1,0
Geschlecht
M
Eingang
28.01.2021
Impfdatum
28.01.2021
Beginn
28.01.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / UN
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Local reaction

Symptomtext

Verififed. Kept 10-15 MIN LOCALIZED REACTION NOTED. NOTIFIED DR

Weitere VAERSDATA-Felder
Praegender Schweregrund
Local reaction
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
NONE
Vorgeschichte
NO KNOWN ALLERGIES
Andere Medikamente
SEE ATTACHED DOCUMENT
Allergien
-
Vorherige Impfungen
Hives/Skin Rash~Measles + Mumps + Rubella + Varicella (no brand name)~1~1.00~Patient

VAERS 964681

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
CA
Alter
1,3
Geschlecht
M
Eingang
21.01.2021
Impfdatum
21.01.2021
Beginn
-
Tage bis Beginn
-
Dosis
1
Route/Site
IM / RL
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered Wrong product administered

Symptomtext

patient was given one additional dose of varicella. Proquad was given instead of MMR. No reaction @ the time of visit

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
NKA
Vorherige Impfungen
-

VAERS 947441

MERCK & CO. INC. · HEP A (VAQTA) · Charge T013205

gering
Staat
CO
Alter
4,0
Geschlecht
U
Eingang
15.01.2021
Impfdatum
11.01.2021
Beginn
11.01.2021
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Wrong product administered

Symptomtext

patient inadvertently received a dose of VAQTA; This spontaneous report was received from a medical assistant and refers to a 4 year old patient of unknown gender. No information was given regarding the patient's concurrent conditions, concomitant medications or medical history. On 11-JAN-2021, the patient was inadvertently vaccinated as the patient's sibling had a very similar name with hepatitis a vaccine, inactivated(VAQTA) lot # T013205 with expiration date on 03-DEC-2021, 0.5 milliliter for prophylaxis (route of administration was not reported). There was no missed dose. combinationproductreport: Yes; brandname: VAQTA SYRINGE (DEVICE); commondevicename: Hepatitis A Vaccine, Inactivated; productcode: FMF; devicetype: SYRINGE, PISTON (FMF); manufacturername: Merck Sharp & Dohme Corp.; devicelotnumber: T013205; expirationdate: 03-DEC-2021; deviceage and unit: 0 ; malfunction: Unknown; deviceusage: Initial; evaluatedbymfr: Not returned to manufacturer; reasonfornoneval: 81 Other; labeledsingleusedevice: No; mdcpreportability: No; mdcpreprationale: Case information does not meet the criteria for Reportability

Weitere VAERSDATA-Felder
Praegender Schweregrund
Wrong product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
VAQTA SYRINGE (DEVICE)
Allergien
-
Vorherige Impfungen
-